Literature DB >> 11478553

Pharmacokinetics of antibiotic prophylaxis in major orthopedic surgery and blood-saving techniques.

M G Dehne1, J Mühling, A Sablotzki, H Nopens, G Hempelmann.   

Abstract

The pharmacokinetics of cefuroxime, cefotiam, cefamandole, and ampicillin/sulbactam were randomly measured in 40 patients undergoing major orthopedic surgery associated with high blood and volume turnover and intraoperative blood salvage. Serum and bone concentrations and the pharmacokinetics occurring in the context of these procedures were measured. No changes in elimination half-life relative to a normal population occurred with cefuroxime, cefotiam, and ampicillin. Serum and tissue concentrations were slightly lower with cefamandole and sulbactam, but reapplication of the initial dose was required with all antibiotics 4 hours after the first application.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11478553     DOI: 10.3928/0147-7447-20010701-15

Source DB:  PubMed          Journal:  Orthopedics        ISSN: 0147-7447            Impact factor:   1.390


  4 in total

1.  [Ampicillin and sulbactam concentrations in the irradiated mandible after oral squamous cell cancer].

Authors:  H Heibel; M Scheer; T Reuther; M Hahn; R Trittler; H Egle; K Kümmerer; A C Kübler
Journal:  Mund Kiefer Gesichtschir       Date:  2005-07

Review 2.  Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations.

Authors:  Cornelia B Landersdorfer; Jürgen B Bulitta; Martina Kinzig; Ulrike Holzgrabe; Fritz Sörgel
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

3.  Current preventive measures for health-care associated surgical site infections: a review.

Authors:  David M Tsai; Edward J Caterson
Journal:  Patient Saf Surg       Date:  2014-10-11

4.  Cefazolin Irreversibly Inhibits Proliferation and Migration of Human Mesenchymal Stromal Cells.

Authors:  Hakan Pilge; Julia Fröbel; Sabine Lensing-Höhn; Christoph Zilkens; Rüdiger Krauspe
Journal:  Biomed Res Int       Date:  2016-03-16       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.